Lithium Has Minimal Direct Effect on Liver Enzymes
Lithium does not significantly elevate liver enzymes (ALT and AST) in clinical practice, and hepatotoxicity is not a recognized adverse effect of lithium therapy. The FDA-approved prescribing information for lithium does not list elevated liver enzymes or hepatotoxicity among its adverse reactions, and routine monitoring of liver function tests is not recommended during lithium treatment 1.
Evidence from FDA Drug Labeling
The comprehensive adverse reaction profile for lithium includes numerous organ systems—neuromuscular, cardiovascular, renal, thyroid, and dermatologic—but hepatic enzyme elevation is notably absent 1. The FDA labeling specifically mentions that "elevated serum enzymes" may occur as part of an encephalopathic syndrome when lithium is combined with haloperidol, but this represents a rare drug interaction rather than a direct hepatotoxic effect of lithium monotherapy 1.
Preclinical Research Context
While animal studies have explored lithium's effects on liver tissue, these findings do not translate to clinically significant enzyme elevations in humans:
Protective effects in experimental models: Lithium actually demonstrated hepatoprotective properties in rat models of liver ischemia/reperfusion injury, reducing AST and ALT levels rather than elevating them 2.
Toxicity only at supratherapeutic doses: One rat study using small doses of lithium (15–30 mg/kg for 7 weeks) reported "marked inhibition" of serum ALT and AST levels—meaning the enzymes decreased rather than increased—though this was accompanied by other signs of toxicity 3. These findings reflect experimental conditions that do not mirror therapeutic lithium use in humans.
Cholestasis model: In guinea pigs with bile duct ligation, lithium reduced markers of oxidative liver damage and actually lowered tissue injury indices 4. This further supports that lithium does not cause hepatocellular injury under experimental conditions.
Clinical Monitoring Implications
No routine liver enzyme monitoring is required for patients on lithium therapy 1. The standard monitoring protocol for lithium focuses on:
- Serum lithium levels (therapeutic range 0.6–1.2 mEq/L for maintenance) 1
- Renal function (serum creatinine, urinalysis) 1
- Thyroid function (TSH, free T4) 1
- Electrolytes and hydration status 1
Important Clinical Caveats
If a patient on lithium presents with elevated liver enzymes, the elevation should be attributed to other causes rather than lithium itself:
- Evaluate for nonalcoholic fatty liver disease (NAFLD), viral hepatitis, alcohol use, and medication-induced liver injury from other agents 5, 6
- Obtain a complete liver panel (ALT, AST, alkaline phosphatase, bilirubin, albumin, INR) and viral hepatitis serologies 5, 6
- Calculate the FIB-4 score to assess for advanced fibrosis if metabolic risk factors are present 5
- Perform abdominal ultrasound as first-line imaging (sensitivity 84.8%, specificity 93.6% for moderate-to-severe steatosis) 5
Do not discontinue lithium based solely on incidental liver enzyme elevation without investigating alternative etiologies, as lithium is not hepatotoxic and premature discontinuation may destabilize the underlying psychiatric condition 1.